Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial.

Neoadjuvant perioperative ivonescimab plus chemotherapy in resectable non-small cell lung cancer achieved a 70.1% major pathological response rate (47/67), meeting the primary endpoint.

• Why it matters: Resectable NSCLC has a high risk of postoperative recurrence, creating a need for effective perioperative treatments beyond surgery alone.
• What they did: In this nonrandomized, noncomparative phase 2 trial, patients received neoadjuvant ivonescimab monotherapy (cohort 1) or ivonescimab with chemotherapy (cohort 2), then surgery and adjuvant ivonescimab.
• The result: In cohort 2, the lower bound of the 80% two-sided confidence interval exceeded a 41% historical control rate; grade 3+ treatment-related adverse events occurred in 30.4% (24/79) with no grade 3+ hemorrhage or treatment-related death.

AI summary of the abstract · may contain errors · not medical advice · read the paper.